A unique host defense pathway: TRIF mediates both antiviral and antibacterial immune responses

Microbes and Infection

Volumn 15, Issue 1, 2013, Pages 1-10

  Hyun, Jinhee ^a   Kanagavelu, Saravana ^a   Fukata, Masayuki ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Host defense mechanism; Innate immunity; Toll like receptor; TRIF

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12P40; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; RANTES; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1;

ANTIBACTERIAL IMMUNITY; ANTIVIRAL IMMUNITY; APOPTOSIS; CELL MIGRATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HOST RESISTANCE; HUMAN; INFECTION; INNATE IMMUNITY; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; BACTERIAL INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; TOLL-LIKE RECEPTORS; VIRUS DISEASES;

BACTERIA (MICROORGANISMS);

EID: 84871818048     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2012.10.011     Document Type: Short Survey

References (72)

1. Jackson R.W., Johnson L.J., Clarke S.R., Arnold D.L. Bacterial pathogen evolution: breaking news. Trends Genet. 2011, 27:32-40.
2. Couzin J. Genetics. Hybrid mosquitoes suspected in West Nile virus spread. Science 2004, 303:1451.
3. Goto Y., Kiyono H. Epithelial barrier: an interface for the cross-communication between gut flora and immune system. Immunol. Rev. 2012, 245:147-163.
4. Macpherson A.J., Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004, 303:1662-1665.
5. Frick I.M., Nordin S.L., Baumgarten M., Morgelin M., Sorensen O.E., Olin A.I., Egesten A. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes. J. Immunol. 2011, 187:4300-4309.
6. Riley L.W., Remis R.S., Helgerson S.D., McGee H.B., Wells J.G., Davis B.R., Hebert R.J., Olcott E.S., Johnson L.M., Hargrett N.T., Blake P.A., Cohen M.L. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N. Engl. J. Med. 1983, 308:681-685.
7. Kyle J.L., Cummings C.A., Parker C.T., Quinones B., Vatta P., Newton E., Huynh S., Swimley M., Degoricija L., Barker M., Fontanoz S., Nguyen K., Patel R., Fang R., Tebbs R., Petrauskene O., Furtado M., Mandrell R.E. Escherichia coli serotype O55:H7 diversity supports parallel acquisition of bacteriophage at Shiga toxin phage insertion sites during evolution of the O157:H7 lineage. J. Bacteriol. 2012, 194:1885-1896.
8. Stecher B., Denzler R., Maier L., Bernet F., Sanders M.J., Pickard D.J., Barthel M., Westendorf A.M., Krogfelt K.A., Walker A.W., Ackermann M., Dobrindt U., Thomson N.R., Hardt W.D. Gut inflammation can boost horizontal gene transfer between pathogenic and commensal Enterobacteriaceae. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:1269-1274.
9. Netea M.G., Wijmenga C., O'Neill L.A. Genetic variation in Toll-like receptors and disease susceptibility. Nat. Immunol. 2012, 13:535-542.
10. Yamamoto A., Kumakura S., Uchida M., Barrett J.C., Tsutsui T. Immortalization of normal human embryonic fibroblasts by introduction of either the human papillomavirus type 16 E6 or E7 gene alone. Int. J. Cancer 2003, 106:301-309.
11. Hoebe K., Du X., Georgel P., Janssen E., Tabeta K., Kim S.O., Goode J., Lin P., Mann N., Mudd S., Crozat K., Sovath S., Han J., Beutler B. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 2003, 424:743-748.
12. Zhang Z., Kim T., Bao M., Facchinetti V., Jung S.Y., Ghaffari A.A., Qin J., Cheng G., Liu Y.J. DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells. Immunity 2011, 34:866-878.
13. Kagan J.C., Su T., Horng T., Chow A., Akira S., Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat. Immunol. 2008, 9:361-368.
14. O'Neill L.A., Bowie A.G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 2007, 7:353-364.
15. Estornes Y., Toscano F., Virard F., Jacquemin G., Pierrot A., Vanbervliet B., Bonnin M., Lalaoui N., Mercier-Gouy P., Pacheco Y., Salaun B., Renno T., Micheau O., Lebecque S. dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8. Cell. Death Differ. 2012, 19:1482-1494.
16. Gaddis D.E., Michalek S.M., Katz J. TLR4 signaling via MyD88 and TRIF differentially shape the CD4+ T cell response to Porphyromonas gingivalis hemagglutinin B. J. Immunol. 2011, 186:5772-5783.
17. Kamon H., Kawabe T., Kitamura H., Lee J., Kamimura D., Kaisho T., Akira S., Iwamatsu A., Koga H., Murakami M., Hirano T. TRIF-GEFH1-RhoB pathway is involved in MHCII expression on dendritic cells that is critical for CD4 T-cell activation. EMBO J. 2006, 25:4108-4119.
18. McAleer J.P., Rossi R.J., Vella A.T. Lipopolysaccharide potentiates effector T cell accumulation into nonlymphoid tissues through TRIF. J. Immunol. 2009, 182:5322-5330.
19. Lawrence R.M., Lawrence R.A. Breast milk and infection. Clin. Perinatol. 2004, 31:501-528.
20. Kuss S.K., Best G.T., Etheredge C.A., Pruijssers A.J., Frierson J.M., Hooper L.V., Dermody T.S., Pfeiffer J.K. Intestinal microbiota promote enteric virus replication and systemic pathogenesis. Science 2011, 334:249-252.
21. Yan N., Chen Z.J. Intrinsic antiviral immunity. Nat. Immunol. 2012, 13:214-222.
22. Rusch L., Zhou A., Silverman R.H. Caspase-dependent apoptosis by 2',5'-oligoadenylate activation of RNase L is enhanced by IFN-beta. J. Interferon. Cytokine Res. 2000, 20:1091-1100.
23. Sha Q., Truong-Tran A.Q., Plitt J.R., Beck L.A., Schleimer R.P. Activation of airway epithelial cells by toll-like receptor agonists. Am. J. Respir. Cell. Mol. Biol. 2004, 31:358-364.
24. Haller O., Staeheli P., Kochs G. Protective role of interferon-induced Mx GTPases against influenza viruses. Rev. Sci. Tech. 2009, 28:219-231.
25. Guillot L., Le Goffic R., Bloch S., Escriou N., Akira S., Chignard M., Si-Tahar M. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J. Biol. Chem. 2005, 280:5571-5580.
26. Furrie E., Macfarlane S., Thomson G., Macfarlane G.T. Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology 2005, 115:565-574.
27. Zarember K.A., Godowski P.J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 2002, 168:554-561.
28. Pott J., Stockinger S., Torow N., Smoczek A., Lindner C., McInerney G., Backhed F., Baumann U., Pabst O., Bleich A., Hornef M.W. Age-dependent TLR3 expression of the intestinal epithelium contributes to rotavirus susceptibility. PLoS Pathog. 2012, 8:e1002670.
29. Sen A., Pruijssers A.J., Dermody T.S., Garcia-Sastre A., Greenberg H.B. The early interferon response to rotavirus is regulated by PKR and depends on MAVS/IPS-1, RIG-I, MDA-5, and IRF3. J. Virol. 2011, 85:3717-3732.
30. Riad A., Westermann D., Zietsch C., Savvatis K., Becher P.M., Bereswill S., Heimesaat M.M., Lettau O., Lassner D., Dorner A., Poller W., Busch M., Felix S.B., Schultheiss H.P., Tschope C. TRIF is a critical survival factor in viral cardiomyopathy. J. Immunol. 2011, 186:2561-2570.
31. Qu L., Feng Z., Yamane D., Liang Y., Lanford R.E., Li K., Lemon S.M. Disruption of TLR3 signaling due to cleavage of TRIF by the hepatitis A virus protease-polymerase processing intermediate, 3CD. PLoS Pathog. 2011, 7:e1002169.
32. Imran M., Waheed Y., Manzoor S., Bilal M., Ashraf W., Ali M., Ashraf M. Interaction of Hepatitis C virus proteins with pattern recognition receptors. Virol. J. 2012, 9:126.
33. Sancho-Shimizu V., Perez de Diego R., Lorenzo L., Halwani R., Alangari A., Israelsson E., Fabrega S., Cardon A., Maluenda J., Tatematsu M., Mahvelati F., Herman M., Ciancanelli M., Guo Y., AlSum Z., Alkhamis N., Al-Makadma A.S., Ghadiri A., Boucherit S., Plancoulaine S., Picard C., Rozenberg F., Tardieu M., Lebon P., Jouanguy E., Rezaei N., Seya T., Matsumoto M., Chaussabel D., Puel A., Zhang S.Y., Abel L., Al-Muhsen S., Casanova J.L. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J. Clin. Invest. 2011, 121:4889-4902.
34. Egger D., Teterina N., Ehrenfeld E., Bienz K. Formation of the poliovirus replication complex requires coupled viral translation, vesicle production, and viral RNA synthesis. J. Virol. 2000, 74:6570-6580.
35. Abe Y., Fujii K., Nagata N., Takeuchi O., Akira S., Oshiumi H., Matsumoto M., Seya T., Koike S. The toll-like receptor 3-mediated antiviral response is important for protection against poliovirus infection in poliovirus receptor transgenic mice. J. Virol. 2012, 86:185-194.
36. Daffis S., Samuel M.A., Suthar M.S., Gale M., Diamond M.S. Toll-like receptor 3 has a protective role against West Nile virus infection. J. Virol. 2008, 82:10349-10358.
37. Blazquez A.B., Saiz J.C. West Nile virus (WNV) transmission routes in the murine model: intrauterine, by breastfeeding and after cannibal ingestion. Virus. Res. 2010, 151:240-243.
38. Wang T., Town T., Alexopoulou L., Anderson J.F., Fikrig E., Flavell R.A. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat. Med. 2004, 10:1366-1373.
39. Hazlett L., Wu M. Defensins in innate immunity. Cell. Tissue Res. 2011, 343:175-188.
40. Mackay F., Schneider P., Rennert P., Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 2003, 21:231-264.
41. He B., Xu W., Santini P.A., Polydorides A.D., Chiu A., Estrella J., Shan M., Chadburn A., Villanacci V., Plebani A., Knowles D.M., Rescigno M., Cerutti A. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 2007, 26:812-826.
42. Schneeman T.A., Bruno M.E., Schjerven H., Johansen F.E., Chady L., Kaetzel C.S. Regulation of the polymeric Ig receptor by signaling through TLRs 3 and 4: linking innate and adaptive immune responses. J. Immunol. 2005, 175:376-384.
43. Reis R.S., Horn F. Enteropathogenic Escherichia coli, Samonella, Shigella and Yersinia: cellular aspects of host-bacteria interactions in enteric diseases. Gut Pathog. 2010, 2:8.
44. Hernandez L.D., Hueffer K., Wenk M.R., Galan J.E. Salmonella modulates vesicular traffic by altering phosphoinositide metabolism. Science 2004, 304:1805-1807.
45. Wong C.E., Sad S., Coombes B.K. Salmonella enterica serovar typhimurium exploits Toll-like receptor signaling during the host-pathogen interaction. Infect. Immun. 2009, 77:4750-4760.
46. Ruckdeschel K., Pfaffinger G., Haase R., Sing A., Weighardt H., Hacker G., Holzmann B., Heesemann J. Signaling of apoptosis through TLRs critically involves toll/IL-1 receptor domain-containing adapter inducing IFN-beta, but not MyD88, in bacteria-infected murine macrophages. J. Immunol. 2004, 173:3320-3328.
47. Talbot S., Totemeyer S., Yamamoto M., Akira S., Hughes K., Gray D., Barr T., Mastroeni P., Maskell D.J., Bryant C.E. Toll-like receptor 4 signalling through MyD88 is essential to control Salmonella enterica serovar typhimurium infection, but not for the initiation of bacterial clearance. Immunology 2009, 128:472-483.
48. Cai S., Batra S., Shen L., Wakamatsu N., Jeyaseelan S. Both TRIF- and MyD88-dependent signaling contribute to host defense against pulmonary Klebsiella infection. J. Immunol. 2009, 183:6629-6638.
49. Power M.R., Li B., Yamamoto M., Akira S., Lin T.J. A role of Toll-IL-1 receptor domain-containing adaptor-inducing IFN-beta in the host response to Pseudomonas aeruginosa lung infection in mice. J. Immunol. 2007, 178:3170-3176.
50. Jeyaseelan S., Young S.K., Fessler M.B., Liu Y., Malcolm K.C., Yamamoto M., Akira S., Worthen G.S. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF)-mediated signaling contributes to innate immune responses in the lung during Escherichia coli pneumonia. J. Immunol. 2007, 178:3153-3160.
51. Bereswill S., Fischer A., Plickert R., Haag L.M., Otto B., Kuhl A.A., Dasti J.I., Zautner A.E., Munoz M., Loddenkemper C., Gross U., Gobel U.B., Heimesaat M.M. Novel murine infection models provide deep insights into the " menage a trois" of Campylobacter jejuni, microbiota and host innate immunity. PLoS One 2011, 6:e20953.
52. Bowen W.S., Minns L.A., Johnson D.A., Mitchell T.C., Hutton M.M., Evans J.T. Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist. Sci. Signal. 2012, 5:ra13.
53. Hawn T.R., Scholes D., Li S.S., Wang H., Yang Y., Roberts P.L., Stapleton A.E., Janer M., Aderem A., Stamm W.E., Zhao L.P., Hooton T.M. Toll-like receptor polymorphisms and susceptibility to urinary tract infections in adult women. PLoS One 2009, 4:e5990.
54. Sotolongo J., Espana C., Echeverry A., Siefker D., Altman N., Zaias J., Santaolalla R., Ruiz J., Schesser K., Adkins B., Fukata M. Host innate recognition of an intestinal bacterial pathogen induces TRIF-dependent protective immunity. J. Exp. Med. 2011, 208:2705-2716.
55. Sotolongo J., Kanagavelu S., Hyun J., Ruiz J., Fukata M. TRIF mobilizes unique primary defense against Gram-negative bacteria in intestinal interface. Gut Microbe. 2012, 3:437-441.
56. Morse M.A., Chapman R., Powderly J., Blackwell K., Keler T., Green J., Riggs R., He L.Z., Ramakrishna V., Vitale L., Zhao B., Butler S.A., Hobeika A., Osada T., Davis T., Clay T., Lyerly H.K. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin. Cancer Res. 2011, 17:4844-4853.
57. Rosenfeld M.R., Chamberlain M.C., Grossman S.A., Peereboom D.M., Lesser G.J., Batchelor T.T., Desideri S., Salazar A.M., Ye X. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol. 2010, 12:1071-1077.
58. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 2007, 13:552-559.
59. Doehle B.P., Hladik F., McNevin J.P., McElrath M.J., Gale M. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J. Virol. 2009, 83:10395-10405.
60. Casale T.B., Kessler J., Romero F.A. Safety of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis. Ann. Allergy Asthma Immunol. 2006, 97:454-456.
61. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D.L., Kitchener H.C., Castellsague X., de Carvalho N.S., Skinner S.R., Harper D.M., Hedrick J.A., Jaisamrarn U., Limson G.A., Dionne M., Quint W., Spiessens B., Peeters P., Struyf F., Wieting S.L., Lehtinen M.O., Dubin G. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170.
62. Cluff C.W. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv. Exp. Med. Biol. 2010, 667:111-123.
63. Gearing A.J. Targeting toll-like receptors for drug development: a summary of commercial approaches. Immunol. Cell. Biol. 2007, 85:490-494.
64. Hensley L.E., Fritz L.E., Jahrling P.B., Karp C.L., Huggins J.W., Geisbert T.W. Interferon-beta 1a and SARS coronavirus replication. Emerg. Infect. Dis. 2004, 10:317-319.
65. Lazear H.M., Pinto A.K., Vogt M.R., Gale M., Diamond M.S. Beta interferon controls West Nile virus infection and pathogenesis in mice. J. Virol. 2011, 85:7186-7194.
66. Tel J., Beenhakker N., Koopman G., Hart B., Mudde G.C., de Vries I.J. Targeted delivery of CpG ODN to CD32 on human and monkey plasmacytoid dendritic cells augments IFNalpha secretion. Immunobiology 2012, 217:1017-1024.
67. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., Bosio C., Dow S. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol. 2006, 176:7335-7345.
68. Ichinohe T., Kawaguchi A., Tamura S., Takahashi H., Sawa H., Ninomiya A., Imai M., Itamura S., Odagiri T., Tashiro M., Chiba J., Sata T., Kurata T., Hasegawa H. Intranasal immunization with H5N1 vaccine plus poly I: poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbe. Infect. 2007, 9:1333-1340.
69. Stevceva L. Toll-like receptor agonists as adjuvants for HIV vaccines. Curr. Med. Chem. 2011, 18:5079-5082.
70. Fornarino S., Laval G., Barreiro L.B., Manry J., Vasseur E., Quintana-Murci L. Evolution of the TIR domain-containing adaptors in humans: swinging between constraint and adaptation. Mol. Biol. Evol. 2011, 28:3087-3097.
71. Baldridge J.R., Cluff C.W., Evans J.T., Lacy M.J., Stephens J.R., Brookshire V.G., Wang R., Ward J.R., Yorgensen Y.M., Persing D.H., Johnson D.A. Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529. J. Endotoxin Res. 2002, 8:453-458.
72. Ye J., Chen S., Maniatis T. Cardiac glycosides are potent inhibitors of interferon-beta gene expression. Nat. Chem. Biol. 2011, 7:25-33.